1094555-68-6

Basic information

• Product Name: (3-bromo-5-fluorophenyl)methanamine
• Synonyms: (3-bromo-5-fluorophenyl)methanamine;BENZENEMETHANAMINE, 3-BROMO-5-FLUORO-;3-Bromo-5-fluorobenzenemethanamine
• CAS NO: 1094555-68-6
• Molecular Formula: C7H7BrFN
• Molecular Weight: 204.0395832
• Mol File: 1094555-68-6.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 241℃
• Flash Point: 100℃
• Appearance: /
• Density: 1.571
• PKA: 8.51±0.10(Predicted)
• CAS DataBase Reference: (3-bromo-5-fluorophenyl)methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (3-bromo-5-fluorophenyl)methanamine(1094555-68-6)
• EPA Substance Registry System: (3-bromo-5-fluorophenyl)methanamine(1094555-68-6)

Safety Data

• Hazardous Substances Data: 1094555-68-6(Hazardous Substances Data)

Usage

General Description

(3-bromo-5-fluorophenyl)methanamine is a chemical compound with the formula C7H6BrFN. It is a member of the amine family and contains a bromine and fluorine atom attached to a benzene ring. (3-bromo-5-fluorophenyl)methanamine is used in pharmaceutical research as a building block for the synthesis of various biologically active molecules. It may also have potential applications in the field of medicinal chemistry and drug discovery. Additionally, (3-bromo-5-fluorophenyl)methanamine may be used as a reagent in organic synthesis for the preparation of complex organic compounds. Its structure and properties make it a valuable tool for the development of new drugs and materials.

Upstream product

• 179898-34-1 3-bromo-5-fluorobenzonitrile 

Downstream Products

• 1467083-70-0 N-(3-bromo-5-fluorobenzyl) methanesulfonamide 

Relevant articles and documents

STRAD-BINDING AGENTS AND USES THEREOF

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.